Editas Medicine, Inc. — Director's Dealing 2016

Feb 9, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2016-02-08

Reporting Person: Bosley Katrine (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-08	Common Stock	C	73856	—	Acquired	1436822	Direct
2016-02-08	Common Stock	C	4273	—	Acquired	1441095	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-08	Series A-2 Preferred Stock	$	C	192027	Disposed		Common Stock (73856)	Direct
2016-02-08	Series B Preferred Stock	$	C	11111	Disposed		Common Stock (4273)	Direct

Footnotes

F1: The Series A-2 and Series B Preferred Stock converted into Common Stock on a 2.6-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.